A PHASE III DOUBLE-BLINDED MULTICENTER RANDOMIZED STUDY EVALUATING THE EFFICACY AND SAFETY OF NEOADJUVANT TREATMENT WITH ATEZOLIZUMAB OR PLACEBO IN COMBINATION WITH PLATINUM-BASED CHEMOTHERAPY IN PATIENTS WITH RESECTABLE STAGE II IIIA OR SELECT IIIB NON-SMALL CELL LUNG CANCER

Brief description of study

The purpose of this study is to compare the effects, good or bad, of atezolizumab plus chemotherapy (in this study, chemotherapy will be a combination of either nab-paclitaxel with carboplatin, pemetrexed with carboplatin or cisplatin, or gemcitabine with cisplatin) versus placebo (an inactive substance that looks like study drug atezolizumab but has no active ingredient) plus chemotherapy in patients with resectable NSCLC to find out which is better.

Clinical Study Identifier: s18-01420

ClinicalTrials.gov Identifier: NCT03456063

Principal Investigator: Elaine Shum.

Other Investigators: Vamsidhar Velcheti, Andre L Moreira, Jennifer Wu, Mary K O'Keeffe, Virginia M Ferreira, Scott L Schubach, Arjun Iyengar, Jeffrey G Schneider, Laurence N Spier, Natalia Cherkassky, Elena A Selbs, Harvey I Pass, Abraham Chachoua, David Mendoza, Melissa L Martinez, Marissa Rybstein, Alexander A Hindenburg, Mary Lynn R Nierodzik, Joshua K Sabari, Stephanie H. Chang.

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

First name is mandatory

Last Name

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

Comments

Send Confirmation of This To Me

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Perlmutter Cancer Center

Clinical Trials & Research Studies